Make Informed Investment Decisions with Affordable Access to Experts
Discussing Rivipansel in Sickle Cell Disease and the Published Phase 2 Data.Ticker(s): GLYC, GBT
Name: Dr Julie Kanter - MD
- Associate Professor of Hematology at the University of Alabama at Birmingham and oversees the Adult Sickle Cell Clinic.
- Currently manages 1000 - 1100 patients with sickle cell disease.
- Principal Investigator in a number of large clinical trials related to sickle cell disease and has been involved in the comprehensive care and research for sickle cell disease patients for the past 10 years.
What per centage of patients with sickle cell disease do you anticipate will be treated with Voxelotor
How much of a shortening of a VOC hospitalization would be necessary for reviapansel to achieve in order for it to be a commercial success
What is your guess for pricing of Voxelotor and Rivapansel?
What would per centage of shortening of an SS crisis would you consider as a success for rivapansel
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.